Oryzon Genomics S.A (ORY) | Stock Overview & Key Data
Oryzon Genomics S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €5.25 on December 14, 2015
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 220.00M Mid-cap | -3.13% | 0.72% | -12.81% | -12.81% | -13.35% | 2.95% | 31.60% | -21.41% | -5.42% | -21.41% | -21.41% | |
|
Pharma Mar S.A
PHM
|
1.68B Large-cap | -2.77% | 9.23% | 17.43% | 27.39% | 23.89% | 30.10% | 151.19% | -0.37% | 186.82% | 180.20% | 30.59% |
|
Atrys Health S.A
ATRY
|
222.81M Mid-cap | -3.65% | 7.41% | -3.65% | -14.20% | -0.68% | 1.75% | -42.91% | -69.15% | 81.25% | 81.25% | 81.25% |
| 144.69M Small-cap | 11.05% | 29.80% | 115.38% | 206.25% | 134.73% | 512.50% | 497.56% | 595.04% | 595.04% | 595.04% | 595.04% | |
| 19.30M Small-cap | 8.33% | 13.04% | 30.00% | -27.78% | 30.00% | -16.13% | -21.21% | -70.79% | -91.88% | -88.50% | -88.50% | |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
Ownership & Short Interest
Calculate Your Oryzon Genomics S.A Investment Returns
Long-Term Investment Performance Analysis
Oryzon Genomics S.A stock price in Jul 2016 was €2.87, A €1,000.00 lump sum investment in Oryzon Genomics S.A made 9 years ago would be worth approximately €972.13 today, representing a negative return of -2.79%. This translates to an annualized return (CAGR) of -0.29%.
9 Years 9 Months Investment Scenario (Jul 2016 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ORY's 52-week high and low?
- In the last 52 weeks, Oryzon Genomics S.A reached a high of €4.02 (on N/A) and a low of €2.51 (on April 24, 2025).
- What is the market cap and P/E ratio for ORY?
- Curious about Oryzon Genomics S.A's size and valuation? Its market capitalization stands at 220.00M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is 55.92.
- Does ORY pay dividends? If so, what's the yield?
- As for dividends, Oryzon Genomics S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Oryzon Genomics S.A's main competitors or similar companies to consider before investing?
When looking at Oryzon Genomics S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.68B Healthcare Biotechnology 30.10% 151.19% Atrys Health S.A
ATRY222.81M Healthcare Biotechnology 1.75% -42.91% Vytrus Biotech S.A
VYT144.69M Healthcare Biotechnology 512.50% 497.56% Biotechnology Assets
BST19.30M Healthcare Biotechnology -16.13% -21.21% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oryzon Genomics S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Oryzon Genomics S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -2.53%, the Debt to Equity ratio from the most recent quarter is 15.07, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ORY?
- Looking at Oryzon Genomics S.A's growth, its revenue over the trailing twelve months (TTM) was €11M. Compared to the same quarter last year (YoY), quarterly revenue grew by 48.60%, and quarterly earnings saw a YoY growth of N/A.
- How much of ORY stock is held by insiders and institutions?
- Wondering who owns Oryzon Genomics S.A stock? Company insiders (like executives and directors) hold about 21.27% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.